share_log

Pharmaniaga's Regularisation Plan Receives Bursa Approval

Pharmaniaga's Regularisation Plan Receives Bursa Approval

Pharmaniaga的規範計劃獲得馬交所批准
Business Today ·  11/29 23:11
big

Pharmaniaga Berhad announced that Bursa Malaysia has approved the Group's Regularisation Plan which will see the group looking towards its financial recovery.

Pharmaniaga Berhad宣佈,馬來西亞證券交易所已批准該集團的正規化計劃,該計劃將使該集團着眼於財務復甦。

Pharmaniaga Managing Director, Zulkilfli Jafar said, "The approval from Bursa Malaysia paves the way for Pharmaniaga to implement its comprehensive RP, designed to strengthen the Group's financial position, enhance operational efficiencies, and secure long-term growth."

Pharmaniaga董事總經理Zulkilfli Jafar表示:「馬來西亞證券交易所的批准爲Pharmaniaga實施其全面的RP鋪平了道路,旨在加強集團的財務狀況,提高運營效率並確保長期增長。」

"With this latest development, we are now fully focused on executing the RP and achieving a swift exit from PN17," he said.

他說:「隨着這一最新進展,我們現在全神貫注於執行RP並迅速退出PN17。」

The RP outlines strategic initiatives aimed at financial restructuring, business optimisation and strengthening Pharmaniaga's core operations. It represents a proactive approach that will initiate rights issuance to provide the Group's shareholders with an opportunity to reinforce their investments; private placement exercise aimed at drawing potential strategic investors to contribute to the Group's value enhancement and growth in the healthcare sector; and a capital reduction process to adjust the Group's share capital.

RP概述了旨在財務重組、業務優化和加強Pharmaniaga核心業務的戰略舉措。它代表了一種積極的方針,將啓動供股,爲集團股東提供加強投資的機會;私募活動旨在吸引潛在的戰略投資者爲集團的價值提升和醫療保健領域的增長做出貢獻;以及調整集團股本的資本削減程序。

Zulkifli further added, "The Group assures its stakeholders, including customers, investors, and business partners, that we remain committed to maintaining the highest standards of service and product quality throughout this period of transformation."

Zulkifli進一步補充說:「集團向包括客戶、投資者和業務合作伙伴在內的利益相關者保證,在這段轉型期間,我們將繼續致力於保持最高的服務和產品質量標準。」

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論